个人经历

学习经历：

2018.09-2023.09重庆大学,生物医学工程,博士

2015.09-2018.06沈阳药科大学,药理学,硕士

2011.09-2015.06沈阳药科大学,药学/国际经济与贸易(药学方向)本科(双学位)

工作经历：

2023.10-至今新疆大学，药物研究所

2018.06-2018.09科伦药物研究院,药理毒理研究

奖励情况

2022年获得成渝创新创业大赛优秀奖；

2021年获得中国生化学会优秀墙报奖；

2017年获得校优秀团干部；

2015年获得校三好学生标兵；

2014年校优秀学生

代表性研究成果

1.Wenfang, Li., Can, Huang., Li, Qiu., Yu, Tang., Xia, Zhang., Lei, Zhang., Hezhao, Zhao., Makoto, Miyagishi., Vivi, Kasim., Shourong, Wu.(2024). p52-ZER6/IGF1R axis maintains cancer stem cell population to promote cancer progression by enhancing pro-survival mitophagy. Oncogene, 43(27), 0.

2. Li Wen-Fang., Alfason Leader., Huang Can., Tang Yu., Qiu Li., Miyagishi Makoto., Wu Shou-Rong., Kasim Vivi. p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors.Acta Pharmacol Sin,2023, 44(3), 647-660.

3. Li Wen-Fang., Herkilini Arin., Tang Yu., Huang Ping., Song Guan-Bin., Miyagishi Makoto., Kasim Vivi., Wu Shou-Rong, The transcription factor PBX3 promotes tumor cell growth through transcriptional suppression of the tumor suppressor p53.Acta Pharmacol Sin,2021, 42(11), 1888-1899.

4. Tang Yu., Li Wenfang., Qiu Li., Zhang Xia., Zhang Lei., Miyagishi Makoto., Zhao Hezhao., Wu Shourong., Kasim Vivi. The p52-ZER6/G6PD axis alters aerobic glycolysis and promotes tumor progression by activating the pentose phosphate pathway.Oncogenesis,2023, 12(1), 17.

5. Leader Alfason, Wenfang Li, Shourong Wu, Vivi Kasim. Resuscitating the guardian: current progress in p53-based therapy.Onco Therapeutics,2021. 8(2), 51 – 92

6. Lei Ke., Li Wenfang., Huang Can., Li Yanjun., Alfason Leader., Zhao Hezhao., Miyagishi Makoto., Wu Shourong., Kasim Vivi. Neurogenic differentiation factor 1 promotes colorectal cancer cell proliferation and tumorigenesis by suppressing the p53/p21 axis.Cancer Sci,2020, 111(1), 175-185.